European Journal of CancerSimons R, Bassi R, Jones D, et al. Cost analysis of treatment-related adverse events with anastrozole (Arimidex) versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective [abstract no. 339]. Eur J ...
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treat... Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was...
We performed a cost-effectiveness analysis of three strategies for the adjuvant treatment of early breast cancer in women age 70 years or older: an aromatase inhibitor (AI-alone) for 5 years, a 5-fraction course of accelerated partial-breast irradiation using intensity-modulated radiation therapy ...
Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-ov... It is desirable to identify the most effective sequence of endocrine therapies for the treatment of postmenopausal women with advanced, hormone...
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recu......
AbstractBackground:The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or ...
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treat... Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was...
Anastrozole Arimidex 54868-5000 (PTC) 9/25/05 First-line treatment of locally advanced or metastatic breast cancer (hormone receptor–positive or unknown) in postmenopausal women, advanced breast cancer following tamoxifen, adjuvant treatment of receptor-positive breast cancer in postmenopausal women D ...
Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancercost-effectiveness analysisadvanced breast canceranastrozolemegestrol acetatedrug costsAnastrozole (Arimidex*) has a survival benefit compared with megestrol acetate in postmenopausal women with advanced...
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. Background: The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal wo... M Lipsitz,TE Delea,A Guo ...